FOLLOW US

Just months after the Supreme Court's Dobbs decision, anti-abortion medical groups, including the Alliance for Hippocratic Medicine, launched a lawsuit seeking to overturn the FDA's initial approval of mifepristone and its subsequent updates in 2016 and 2021 that expanded access to the medication. Their allegations include asserting the dangers of medication abortions, criticizing the FDA for allowing mifepristone's approval, and arguing that the agency's updates removed vital safeguards for women and girls.

  Abortion Pill Battle :  A Precarious Legal Battle Unfolds

The battle gained traction when U.S. District Judge Matthew J. Kacsmaryk granted an injunction favoring the anti-abortion litigants in early April, essentially halting all sales of mifepristone. This move was met with swift counteraction from Danco Laboratories, which, though not an initial party to the lawsuit, joined the federal government in appealing Judge Kacsmaryk's ruling and obtained a partial stay from the Fifth Circuit. The Supreme Court then took the unprecedented step of staying all lower court decisions until the case could be fully reviewed.

In August, the Fifth Circuit panel issued a decision that partially vacated Judge Kacsmaryk's injunction, allowing mifepristone to be prescribed via telehealth visits. However, it retained parts of the order that removed the FDA's subsequent modifications, including the elimination of a mandatory follow-up appointment requirement.

A Nationwide Impact on Healthcare

This decision, argue 23 states and the District of Columbia in a Thursday brief, significantly hampers access to mifepristone, particularly in communities that rely on it. It exacerbates ongoing health crises and places further strain on abortion providers, who are already grappling with the post-Dobbs landscape.

To compound the issue, restricting access to abortion medication, which a group of doctors likens to being as safe as ibuprofen, intensifies the pressure on healthcare providers who deliver other life-saving services, such as cancer screenings and STD tests.

In their statement, the states stress, "Imposing medically unnecessary restraints on access to mifepristone could push providers to the breaking point and may leave many people without access to abortion care at all."

  Abortion Pill Battle : A Battle Over Scientific Rigor

Several amici take issue with the Fifth Circuit panel's judgment, accusing it of needlessly impeding the FDA's rigorous drug approval process. Despite a wealth of evidence and voluminous reports, the panel deemed the FDA's testing insufficient.